Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07137312 · ClinicalTrials.gov registry record

Ex Vivo Expansion (ACT-X)

A clinical trial of Healthy and Solid Tumor, sponsored by Mayo Clinic.

Recruiting
Registry status
24
Enrollment target
1
Study location

NCT07137312: Recruiting study of Healthy and Solid Tumor, sponsored by Mayo Clinic.

NCT07137312 is a study of Healthy and Solid Tumor that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07137312, a study of Healthy and Solid Tumor, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to understand how the body's immune cells respond to a new type of vaccine (neoantigen vaccine) designed to help the immune system recognize and fight cancer. To do this, the study team will collect a research specimen from participants to study their immune cells' reactions to the neoantigen vaccine. This research will help researchers learn more about how these vaccines might work to protect or treat against cancer.

Primary Outcome

Specimen samples obtained by blood draw and/or apheresis will be analyzed to identify immune effector networks that accelerate ex vivo expansion of antigen-specific memory precursor T cells. All tests will be two sided with a p\<0.05 being considered as statistically significant.

Conditions Studied

Healthy Solid Tumor Malignant Solid Neoplasm

Interventions

  • PROCEDURE Apheresis
  • PROCEDURE Blood Draw

Study Locations (1)

Florida

  • Mayo Clinic in Florida - Jacksonville

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-12-16
Est. Completion 2028-10
Mayo Clinic

2,844 total trials

What NCT07137312 shows while recruiting

NCT07137312 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).

The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Apheresis is the first listed.

NCT07137312 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT07137312 about?

NCT07137312 is a clinical study titled "Ex Vivo Expansion (ACT-X)". The purpose of this study is to understand how the body's immune cells respond to a new type of vaccine (neoantigen vaccine) designed to help the immune system recognize and fight cancer. To do this, the study team will collect a research specimen from participants to study their immune cells' react...

What is the current status of trial NCT07137312?

This trial is currently recruiting. The enrollment target is 24 participants. The study started on 2025-12-16. Estimated completion is 2028-10.

What conditions does trial NCT07137312 study?

This clinical trial studies the following conditions: Healthy, Solid Tumor, Malignant Solid Neoplasm.

What interventions are being tested in trial NCT07137312?

The interventions under investigation include: Apheresis (PROCEDURE), Blood Draw (PROCEDURE).

Who is sponsoring clinical trial NCT07137312?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07137312 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07137312's enrollment target sits among peer trials

24 791st of 1090 higher than 254 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07137312

Source: ClinicalTrials.gov NCT07137312, the US trial registry maintained by the National Library of Medicine. NCT07137312 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.